1 - 10 of 36 articles
Key PointsQuestionIs the poly–(adenosine diphosphate–ribose) polymerase inhibitor olaparib effective against advanced pancreatic cancer with DNA damage repair other than germline BRCA variants (termed “BRCAness” in the literature)?
FindingsTwo parallel nonrandomized phase 2 clinical trials of...
This cohort study examines treatment with immune checkpoint inhibitors for patients with metastatic renal cell carcinoma.
This pharmacovigilance study uses data from the World Health Organization database of adverse drug reactions to examine the association of antiangiogenic drugs with artery dissections or aneurysms among patients receiving antiangiogenic drugs for the treatment of cancer.
Key PointsQuestionCan tislelizumab in combination with chemotherapy offer superior clinical benefit compared with chemotherapy alone as first-line treatment for patients with advanced squamous non–small-cell lung cancer?
FindingsIn this phase 3 randomized clinical trial, tislelizumab plus...
Read and print from thousands of top scholarly journals.
Continue with Facebook
Sign up with Google
Log in with Microsoft
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.